跳至主要内容
临床试验/NCT01247545
NCT01247545已完成3 期

Effect of Remote Ischaemic Preconditioning on Clinical Outcomes in Coronary Artery Bypass Graft Surgery

University College, London28 个研究点 分布在 1 个国家目标入组 1,612 人开始时间: 2010年11月最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
1,612
试验地点
28
主要终点
Major adverse cardiac and cerebral events

研究概览

简要总结

Coronary heart disease (CHD) is the leading cause of death in the UK, accounting for 124,000 deaths (2006) and costing the UK economy over £7.9 billion a year. Patients with severe CHD are usually treated by coronary artery bypass graft (CABG) surgery, the risks of which are increasing due to older and sicker patients being operated on. New treatment strategies are therefore required to improve health outcomes in these high-risk patients undergoing CABG with or without valve (CABG±valve) surgery.

The hypothesis tested in this research proposal is that remote ischaemic preconditioning (RIC), a virtually cost-free, non-pharmacological and simple non-invasive strategy for reducing the damage to the heart muscle at the time of surgery, improves health outcomes in high-risk patients undergoing CABG±valve surgery.

In this research project, 1610 high-risk patients undergoing CABG±valve surgery will be recruited via 28 UK hospitals performing heart surgery. Patients will be randomly allocated to receive either RIC or control. For RIC, a blood pressure cuff will be placed on the upper arm to temporarily deprive it of oxygen and nutrients, an intervention which has been shown in the investigators pilot studies to reduce damage to the heart muscle by up to 40% during CABG±valve surgery. The investigators will determine whether RIC can improve health outcomes in terms of better patient survival, less heart attacks and strokes, shorter hospital stay; less damage to the heart, kidney and brain during surgery; better heart function post-surgery and less chance of developing heart failure; better exercise tolerance and quality of life.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients undergoing CABG with or without valve surgery using blood cardioplegia
  • Patients aged 18 years and above
  • Patients with an additive Euroscore greater than or equal to 5

排除标准

  • Cardiogenic shock
  • Cardiac arrest on current admission
  • Significant peripheral arterial disease affecting the upper limbs
  • Patients with significant hepatic dysfunction (Prothrombin>2.0 ratio)
  • Patients with significant pulmonary disease (FEV1<40% predicted)
  • Patients with known renal failure with a GFR<30 mL/min/1.73 m2
  • Patients on glibenclamide or nicorandil, as these medications may interfere with RIC
  • Patients recruited into another study which may impact on the ERICCA study

结局指标

主要结局

Major adverse cardiac and cerebral events

时间窗: One year post-surgery

Combined endpoint of Cardiovascular death, MI, Revascularisation and Stroke.

次要结局

  • All cause death(1 year post surgery)
  • Length of ITU stay(ITU stay)
  • Peri-operative myocardial injury(72 hours peri-operative period)
  • LV ejection fraction(At one year)
  • 6 minute Walk Test(6 weeks and 12 months post surgery)
  • Acute kidney injury(Peri-operative)
  • 30 day MACCE(30 days post surgery)
  • Length of hospital stay(Until hospital discharge)
  • Inotrope score(72 hours post surgery)
  • Quality of Life(6 weeks, 3/6/9 and 12 months post surgery)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (28)

Loading locations...

相似试验